The latest price target for Atossa Therapeutics (NASDAQ:ATOS) was reported by Ascendiant Capital on September 11, 2024. The analyst firm set a price target for $6.50 expecting ATOS to rise to within 12 months (a possible 330.46% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Atossa Therapeutics (NASDAQ:ATOS) was provided by Ascendiant Capital, and Atossa Therapeutics maintained their buy rating.

There is no last upgrade for Atossa Therapeutics

There is no last downgrade for Atossa Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on September 11, 2024 so you should expect the next rating to be made available sometime around September 11, 2025.

While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a maintained with a price target of $6.25 to $6.50. The current price Atossa Therapeutics (ATOS) is trading at is $1.51, which is out of the analyst’s predicted range.